Navigation Links
Top FDA Officials Were Not Part Of Plan B Decision

The former U.S. Food and Drug Administration chief Commissioner Lester Crawford prevented two senior officials// from deciding the course of action on Barr Pharmaceuticals Inc.'s Plan B, which is a 'morning after' pill.

These statements were contained in the transcripts released by the non-profit Center for Reproductive Rights. Dr. Steven Galson, director of the FDA's Center for Drug Evaluation and Research said that he was thing of approving the action to sell Plan B as a OTC drug. But Crawford "told me that he was concerned about where we were heading because he knew that I was heading towards this recommendation, and he told me that he was going to make the decision on what to do with the application."

He said that Crawford was apparently concerned about the packaging of the drug. Plan B is an emergency pill that can prevent conception if taken within 72 hours after sexual intercourse. Crawford was confirmed in July 2005, but resigned abruptly in September 2005.

Dr. Janet Woodcock, a deputy FDA commissioner also said that she repeatedly asked Crawford about Plan B. "Ordinarily, I would have been more involved, but not in all cases. In this case, I was not involved," Woodcock, said. The Center for Reproductive Rights said that the FDA behaved unusually in this case. "The more we learn about the FDA's decision-making around Plan B, the more we know that the agency violated its own precedents," attorney Simon Heller said.
'"/>




Page: 1

Related medicine news :

1. Health Officials Recommend Flu Vaccine
2. Nutrient Profiling System Launched By Food Officials in UK
3. US Officials To Discuss Effectiveness Of Plan To Face Bird Flu Threat
4. Health Officials Inquire Into OraQuick HIV Tests
5. Officials In Turkey Confirm Deaths Due To Bird Flu
6. Chinese Health Officials To Discuss Preparation Of Bird Flu
7. Bihar Health Officials Worried As Polio Cases Soar
8. Medical Ethics Violated By Prison Officials In Guantanamo Bay
9. Wal-Mart under Pressure from Health Care Officials
10. Minister Suspends 13 Officials For Pulse Polio Laxity
11. Health Officials Defend Their Decision To House Patients In Hotels
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2017)... ... , ... Harbour , a DAO (decentralized autonomous organization) that harnesses the ... their technical specifications . , 2017 has seen an explosion of token launches ... which offerings will garner the greatest ROI. Dean Eigenmann, Co-founder and CEO of Harbour, ...
(Date:6/27/2017)... , ... June 27, 2017 , ... A January 18th ... projected to reach a staggering $6.81 billion by the year 2024 according to a ... a faster rate than those made from titanium. Los Angeles area clinic Beverly Hills ...
(Date:6/27/2017)... ... June 27, 2017 , ... Drs. Gregory Toback and ... in Mystic, CT. Covering the process and maintenance strategies of gum grafting and ... periodontal procedures. Drs. Toback and Urbanski practice as experienced periodontists in ...
(Date:6/27/2017)... Los Angeles, CA (PRWEB) , ... June 27, 2017 , ... ... on what crooked bites can indicate about early life experiences. What happens to a ... study reveals that stresses after birth can also take a toll on a baby’s ...
(Date:6/26/2017)... ... June 26, 2017 , ... The Centers for Advanced Orthopaedics ... of Richard Robinson as chief operating officer (COO). In this role, Robinson brings ... track record of simplifying business processes and developing growth strategies to increase market ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... , June 9, 2017 AirXpanders, Inc. (ASX: ... on the design, manufacture, sale and distribution of the ... the progress of its commercial roll-out in ... in more than one hundred (100) medical institutions and ... AeroForm offers a needle-free alternative for women who choose ...
(Date:6/7/2017)... , June 7, 2017 Endo International ... June 7, 2017, the Hon. Joseph R. Goodwin ... of West Virginia , entered a ... Inc. Pelvic Repair System Products Liability Litigation (the "MDL") ... MDL cases to provide expert disclosures on specific causation ...
(Date:6/3/2017)... 3, 2017  Eli Lilly and Company (NYSE: ... from the Phase 3 MONARCH 2 study showed ... inhibitor, in combination with fulvestrant, significantly improved progression-free ... in women with hormone-receptor-positive (HR+), human epidermal growth ... have relapsed or progressed after endocrine therapy (median ...
Breaking Medicine Technology: